Company / Revenue
Ovid Therapeutics Inc. Revenue History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$566.0K
FY2025
5-year range
$392.0K / $208.4M
FY2022-FY2025
Trend
+44.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue returned to growth in FY2025 after 2 years of decline, reaching $566,000.
Based on SEC 10-K filings.
$566,000 in FY2025 with a 3-year CAGR of -86.0%.
Declined from $2M to $566,000 over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- -86.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -86.0%, indicating a declining trend.
- In FY2025, revenue increased 44.4% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.61 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $566.0K | +44.4% |
| FY2024 | $392.0K | -73.9% |
| FY2023 | $1.5M | -99.3% |
| FY2022 | $208.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026